Does multiple myeloma response induction therapy depending on plasma cell il6 receptor gene expression;L'expression de l'IL6-R par les plasmocytes influe-t-elle la réponse au traitement d'induction au cours du myélome multiple?

Tunisie Medicale

Volumn 91, Issue 5, 2013, Pages 337-341

  Safra, Ines ^a   Ladeb, Saloua ^b   Skouri, Nour ^a   Ouerhani, Slah ^a   Amor, Amina Ben ^a   Menif, Samia ^a   Lakhal, Amel ^b   Torjemane, Lamia ^b   Ben Othman, Tarek ^b   Ben Abdelahim, Abdeladhim ^b   Ben Ahmed, Melika ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^b CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

Author keywords

Cytokines; Multiple myeloma; Oncogenesis; Quantitative PCR; Treatment resistance

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 6 RECEPTOR; THALIDOMIDE;

ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; MULTIPLE MYELOMA; PLASMA CELL; POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-6;

EID: 84878585460     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Kyle RA, rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9
2. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000
3. Klein B, Zhang XG, Lu ZY, Bataille r. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-872
4. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20
5. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-26
6. Seon Young Kim, Hyun Jung Min, alHyun Kyung Park Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation Biol Blood Marrow Transplant 2011; 17: 810-820
7. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-564
8. Gaillard JP, Bataille R, Brailly H, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993;23:820-824
9. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991;77:2794-2795
10. Barillé S, Collette M, Bataille R, Amiot M. Myeloma cells up regulate interleukin-6 secretion in osteoblastic cells through cellto- cell contact but down regulate osteocalcin. Blood. 1995;86:3151-3159
11. Tassone P, Neri P, Burger R, et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer res 2005;11:4251-4258.